A fresh treatment option is now available for young people and adults living with rare kidney diseases, offering hope for improved outcomes.
On March 13, 2026, it was announced that the indication for pegcetacoplan (Aspaveli®) has been expanded to include patients aged 12 to 17 with C3 glomerulopathy (C3G) or primary immune complex-mediated membranoproliferative glomerulonephritis (pIC-MPGN). These are uncommon conditions affecting the kidneys due to ongoing activation of the complement system, a part of the immune system.
Pegcetacoplan is already approved for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). This expanded approval signifies a significant step forward in addressing these rare and challenging kidney disorders, which often require specialized care. Learn more about pegcetacoplan.
C3-Glomerulopathies are characterized by persistent activation of the complement system, leading to kidney damage. Further details on C3-Glomerulopathy can be found online.
Complement-mediated kidney diseases represent a complex area of nephrology, and this new therapeutic option provides clinicians with another tool to manage these conditions. More information on glomerulonephritis is available from JournalMed.
